基于CT的食管癌锁骨上淋巴结转移根治性放化疗分析:单机构回顾性倾向性评分匹配研究
该单机构回顾性研究纳入2009年1月至2015年12月751例接受根治性放化疗的食管癌患者,分析锁骨上淋巴结转移的预后价值。中位随访56.6个月,全组中位总生存16.6个月;锁骨上淋巴结转移患者的总生存、无远处转移生存和无进展生存均显著更差(P<0.001),倾向性评分匹配后结果一致。颈段或上胸段食管癌伴锁骨上淋巴结转移者的预后优于中或下胸段食管癌伴锁骨上淋巴结转移者。
要点
- 锁骨上淋巴结转移的食管癌患者总生存、无远处转移生存和无进展生存均显著更差(P<0.001)。
- 颈段或上胸段食管癌伴锁骨上淋巴结转移者的预后优于中或下胸段伴锁骨上淋巴结转移者。
- 中或下胸段食管癌伴锁骨上淋巴结转移及淋巴结数目是无远处转移生存和无进展生存的独立预后因素。
核心结论
- 对于颈段或上胸段食管癌患者,锁骨上淋巴结转移应考虑为区域淋巴结,若淋巴结总数有限,可予以根治性治疗。
- 对于中或下胸段食管癌患者,锁骨上淋巴结转移应考虑为更高N分期或M1期,因此根治性放化疗后有必要给予巩固化疗。
研究设计与样本
- 单机构回顾性研究,纳入2009年1月至2015年12月共751例接受根治性放化疗的食管癌患者,并进行倾向性评分匹配分析。
主要发现
- 存活患者中位随访时间为56.6个月,全组中位总生存为16.6个月。
- 锁骨上淋巴结转移患者的总生存(χ2=17.342,P<0.001)、无远处转移生存(χ2=24.793,P<0.001)和无进展生存(χ2=25.802,P<0.001)均显著差于无锁骨上淋巴结转移者,倾向性评分匹配后结果相同。
- 颈段或上胸段食管癌伴锁骨上淋巴结转移患者的总生存(χ2=4.516,P=0.038)、无远处转移生存(χ2=8.326,P=0.004)和无进展生存(χ2=6.255,P=0.012)优于中或下胸段食管癌伴锁骨上淋巴结转移者。
- 单因素分析显示,性别、中或下胸段食管癌伴锁骨上淋巴结转移、肿瘤长度、肿瘤直径、同步放化疗和淋巴结数目是无进展生存的预后因素;性别、年龄、中或下胸段食管癌伴锁骨上淋巴结转移、肿瘤直径、肿瘤长度和淋巴结数目是无远处转移生存的预后因素。
- 多因素分析显示,仅中或下胸段食管癌伴锁骨上淋巴结转移和淋巴结数目是无远处转移生存和无进展生存的独立预后因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognostic value of supra-clavicular lymph node (SCLN) metastases in esophageal cancer (EC) is still not clear. METHOD: From January 2009 to December 2015, a survival analysis was performed to retrospectively identify the prognostic value of SCLN metastasis on survival on 751 patients with EC treated with definitive chemo-radiotherapy (dCRT). RESULTS: The median follow-up duration for living patients was 56.6 months. The median overall survival (OS) for all patients was 16.6 months. Patients with SCLN metastasis had a much poorer prognosis for OS (χ2 = 17.342, P < 0.001), distant metastasis-free survival (DMFS) (χ2 = 24.793, P < 0.001) and progression-free survival (PFS) (χ2 = 25.802, P < 0.001) than those without SCLN metastasis. The same results were found after propensity score matching. Nonetheless, the prognosis of patients with cervical or upper thoracic EC metastasis in SCLN was better than those of patients with middle or lower thoracic EC metastasis in SCLN for OS (χ2 = 4.516, P = 0.038), DMFS (χ2 = 8.326, P = 0.004) and PFS (χ2 = 6.255, P = 0.012). Univariate analysis showed that gender, middle or lower thoracic EC with SCLN metastasis, tumor length, tumor diameter, concurrent chemo-radiotherapy (CCR) and number of lymph nodes were prognostic factors for PFS. Gender, age, middle or lower thoracic EC with SCLN metastasis, tumor diameter, tumor length, and number of lymph nodes were prognostic factors for DMFS. According to the multivariate analysis, only middle or lower thoracic EC with SCLN metastasis and number of lymph nodes were independent prognostic factors for DMFS and PFS. CONCLUSION: For patients with cervical or upper thoracic EC, metastasis in SCLN should be considered to be regional lymph nodes and treated with curative intent if the total number of lymph nodes is limited. However, for patients with middle or lower thoracic EC, metastasis should be considered to be a higher level N stage or M1 stage, and it is thus necessary to provide consolidation chemotherapy after dCRT.
引用
- Xu HY, Wu SX, Luo HS, et al. Analysis of definitive chemo-radiotherapy for esophageal cancer with supra-clavicular node metastasis based on CT in a single institutional retrospective study: a propensity score matching analysis. Radiat Oncol. 2018. PMID: 30326912. doi:10.1186/s13014-018-1145-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。